Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Imunon (IMNN – Research Report). The associated price target is $12.00.
Emily Bodnar’s Buy rating for Imunon’s stock (IMNN) is grounded on several key factors. Firstly, the recently announced interim OVATION 2 data from Imunon has boosted confidence in the positive topline results that are expected in mid-2024. Specifically, the OVATION 2 study, which evaluates the efficacy of IMNN-001 in combination with neoadjuvant chemotherapy (NACT) in advanced ovarian cancer patients, has shown promising results. The interim analysis demonstrated a significant delay in disease progression for patients treated with the combination, as compared to those treated with NACT alone.
Additionally, the interim data revealed an almost 9-month improvement in median overall survival (OS) for patients receiving the IMNN-001 + NACT combination compared to NACT alone. This suggests that IMNN-001 could potentially have wide-ranging applicability in ovarian cancer treatment. The close alignment of the interim hazard ratio (HR) for progression-free survival (PFS) with the protocol HR further indicates that the combination treatment is on track to meet the primary endpoint. Consequently, these factors collectively contribute to Bodnar’s Buy rating for Imunon.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Imunon (IMNN) Company Description:
Celsion Corp . engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
Read More on IMNN:
- IMUNON’s VP of R&D to Present at the Vaccines Summit-2023
- IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update
- IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023
- IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress
- Imunon CSO to present at third International Vaccines Congress
